EMPA-REG OUTCOME: The Cardiologist's Point of View.
作者： Son V. Pham , Robert Chilton
DOI: 10.1016/J.AMJMED.2017.04.006
关键词: Heart failure 、 Type 2 Diabetes Mellitus 、 Compliance (physiology) 、 Internal medicine 、 Cardiovascular physiology 、 Cardiology 、 Myocardial oxygen consumption 、 Medicine 、 Empagliflozin 、 In patient 、 Blood pressure
摘要: Cardiologists could view empagliflozin as a cardiovascular drug that also has beneficial effect on reducing hyperglycemia in patients with type 2 diabetes mellitus (T2DM). The effects of lowering the risk death and hospitalization for heart failure T2DM high during recent Empagliflozin Cardiovascular Outcome Event Trial Type Diabetes Mellitus Patients-Removing Excess Glucose (EMPA-REG OUTCOME) trial may be explained principally terms changes to physiology; namely, by potential ability reduce cardiac workload myocardial oxygen consumption blood pressure, improving aortic compliance, ventricular arterial coupling. These concepts hypotheses are discussed this report.
amjmed.com
sci-hub.se 参考文章(39)
Shakia T. Hardy, Laura R. Loehr, Kenneth R. Butler, Sujatro Chakladar, Patricia P. Chang, Aaron R. Folsom, Gerardo Heiss, Richard F. MacLehose, Kunihiro Matsushita, Christy L. Avery, Reducing the Blood Pressure–Related Burden of Cardiovascular Disease: Impact of Achievable Improvements in Blood Pressure Prevention and Control Journal of the American Heart Association. ,vol. 4, ,(2015) , 10.1161/JAHA.115.002276
Jacek Kasznicki, Jozef Drzewoski, State of the art paper Heart failure in the diabetic population – pathophysiology, diagnosis and management Archives of Medical Science. ,vol. 3, pp. 546- 556 ,(2014) , 10.5114/AOMS.2014.43748
Viviany R. Taqueti, Rory Hachamovitch, Venkatesh L. Murthy, Masanao Naya, Courtney R. Foster, Jon Hainer, Sharmila Dorbala, Ron Blankstein, Marcelo F. Di Carli, Global coronary flow reserve is associated with adverse cardiovascular events independently of luminal angiographic severity and modifies the effect of early revascularization. Circulation. ,vol. 131, pp. 19- 27 ,(2015) , 10.1161/CIRCULATIONAHA.114.011939
Barry A. Borlaug, David A. Kass, Ventricular–Vascular Interaction in Heart Failure Heart Failure Clinics. ,vol. 4, pp. 23- 36 ,(2008) , 10.1016/J.HFC.2007.10.001
Peter Gæde, Pernille Vedel, Hans-Henrik Parving, Oluf Pedersen, Intensified multifactorial intervention in patients with type 2 diabetes mellitus and microalbuminuria: the Steno type 2 randomised study The Lancet. ,vol. 353, pp. 617- 622 ,(1999) , 10.1016/S0140-6736(98)07368-1
Bithika Thompson, Dwight A. Towler, Arterial calcification and bone physiology: role of the bone–vascular axis Nature Reviews Endocrinology. ,vol. 8, pp. 529- 543 ,(2012) , 10.1038/NRENDO.2012.36
Nancy R. Cook, Implications of Small Reductions in Diastolic Blood Pressure for Primary Prevention Archives of Internal Medicine. ,vol. 155, pp. 701- 709 ,(1995) , 10.1001/ARCHINTE.1995.00430070053006
Tommaso Gori, John S Floras, John D Parker, Effects of nitroglycerin treatment on baroreflex sensitivity andshort-term heart rate variability in humans Journal of the American College of Cardiology. ,vol. 40, pp. 2000- 2005 ,(2002) , 10.1016/S0735-1097(02)02532-9
Petar M. Seferović, Walter J. Paulus, Clinical diabetic cardiomyopathy: a two-faced disease with restrictive and dilated phenotypes. European Heart Journal. ,vol. 36, pp. 1718- 1727 ,(2015) , 10.1093/EURHEARTJ/EHV134
Laura Ernande, Geneviève Derumeaux, Diabetic cardiomyopathy: Myth or reality? Archives of Cardiovascular Diseases. ,vol. 105, pp. 218- 225 ,(2012) , 10.1016/J.ACVD.2011.11.007